Perimeter Medical Imaging Reports Financial Progress in Q1 2026

Perimeter Medical Imaging AI, Inc. has revealed its financial results for the first quarter of 2026, reflecting a solid growth trajectory and advances in its operations. The company, well-versed as a commercial-stage medical technology entity, reported these results on May 28, 2026, with a conference call scheduled to delve into the specifics of their financials and corporate developments.

Strong Revenue Growth

In the first quarter, the company achieved approximately $385,000 in revenue, all of which originated from recurring sources such as S-Series consumables and system leases. This figure, although lower than the $550,000 recorded during the same period last year, indicates a significant transition within the company as they begin to pivot towards newer technologies, particularly with the introduction of their latest device. Adrian Mendes, the CEO, noted that the recurring revenue segment from the legacy S-Series OCT users showed a commendable year-over-year growth of 14%.

Notably, the company received FDA premarket approval for its innovative Claire™ OCT device in March 2026. This groundbreaking technology is recognized as the first AI-enabled imaging device approved for intraoperative breast cancer margin assessment across the United States. The approval is expected to open new avenues for surgical practices, providing enhanced capabilities to surgeons and potentially decreasing the necessity for re-operations.

Corporate Developments and Launch Plans

As part of their strategic progression, Perimeter introduced the Claire OCT at the 27th Annual Meeting of the American Society of Breast Surgeons in April 2026. Following its unveiling, two prestigious hospitals performed the initial commercial placements of the Claire device. This marks a significant milestone for the company, as establishing Claire as a standard in breast-conserving surgery could secure its role in future cancer treatment protocols.

The company’s sales pipeline for the Claire device has rapidly expanded, currently presenting nearly 50 qualified leads. Of this number, over a dozen are already at various stages of negotiation and development, indicating a robust market interest in the new technology.

Financial Management Efforts

Perimeter's operating expenses reflected prudent cost management, clocking in at approximately $3.2 million for the quarter, a decrease of 30% from the previous year. Despite this reduction in spending, the net loss stood at approximately $3.0 million, translating to $0.02 per share, which presents a significant improvement over the loss recorded last year.

Moreover, the company has actively engaged in measures to strengthen its financial footing. In March 2026, they reached agreements to cancel 1,935,553 stock options while replacing them with those at a lower strike price, enhancing shareholder value. They also executed a successful financing strategy, raising around $7.5 million through various offerings to facilitate further expansion and operational costs.

Conference Call Details

To discuss the financial results and provide further insights on corporate progress, Perimeter is hosting a live conference call today at 5 PM ET. Stakeholders and interested parties can dial in or tune into the webcast via the company’s investor relations page.

Looking Ahead

Perimeter Medical Imaging AI is positioning itself as a frontrunner in the medical technology landscape, especially with its innovative Claire™ device. The FDA's approval and the encouraging financial landscape signal that the company is on the right trajectory for growth and innovation in the cancer treatment domain. As they continue to push forward with their advanced imaging solutions, stakeholders remain optimistic about their future developments and the potential for improved patient outcomes in the field of oncology.